BA, MA, DPhil (Oxon), FRCPath
Professor of Haemato-oncology
- Head of NDCLS
The study of transcriptional de-regulation in B-cell malignancies and the development of novel antibodies for cancer therapy.
Alison Banham is currently Professor of Haemato-oncology and Head of the Nuffield Division of Clinical Laboratory Sciences, within the Radcliffe Department of Medicine at the University of Oxford. Her academic qualifications include BA, MA and D.Phil. (PhD) degrees from the University of Oxford and Fellowship of the Royal College of Pathologists.
Professor Banham is a founder member and Vice President of the European Network of Monoclonal Antibody Producing Laboratories. She is internationally recognised for her expertise in the production and characterisation of monoclonal antibodies and has written guidelines to promote effective antibody validation. She has also made key contributions to the design and delivery of EuroMabNet workshops that teach young scientists how to validate antibodies.
Since 1995 Professor Banham's main research focus has been within the field of cancer, particularly aggressive B-cell malignancies, focussing initially on the identification and characterisation of novel diagnostic and prognostic biomarkers. These have included the FOXP family of forkhead transcription factors (FOXP1-4) and the cancer testis antigen PASD1. These de-regulated transcription factors have functional roles in tumour biology and strategies are being investigated to enable their future therapeutic targeting in diffuse large B-cell lymphoma and multiple myeloma.
Professor Banham's team are also generating novel therapeutic antibodies. These include antibodies targeting the tumour vasculature, in particular the Notch ligand Jagged-1 and the adhesion G-protein coupled receptor ELTD1. She is also pursuing the development of TCR mimic antibodies which recognise peptides from intracellular tumour proteins that are presented on the cell surface by MHC class I molecules. This enables targeting of the intracellular proteome and antibodies to the p53 oncosuppressor are being further characterised.
FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ. et al, (2016), Leukemia, 30, 605 - 616
The European antibody network's practical guide to finding and validating suitable antibodies for research.
Roncador G. et al, (2016), MAbs, 8, 27 - 36
A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis.
Masiero M. et al, (2013), Cancer Cell, 24, 229 - 241
Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukaemia
Freire Boullosa L. et al, (2017), Oncotarget
DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas
Loo SK. et al, (2017), Pathology, 49, 731 - 739
ELTD1/ADGRL4, a novel adhesion GPCR regulator of tumour angiogenesis, suppresses lipid metabolism in endothelial cells, and is upregulated in breast cancer endothelium and epithelium
Favara DM. et al, (2017)
TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma
Loo SK. et al, (2017), Histopathology, 71, 98 - 111
Development of a T Cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy.
Li D. et al, (2017), Cancer Res